Column Group

Juri inks $210M T-cell engager deal with China biotech

Juri Biosciences is offering EpimAb up to $210 million biobucks for licensing rights to a T-cell engager designed to treat metastatic prostate cancer.

Gabrielle Masson May 27, 2025 6:00am

dollar sign with colored arrows in a maze

Cell therapy biotech bags $102M to fund phase 3 epilepsy plans

Apr 3, 2025 1:22pm

Eikon remains in megaround mode with $350M series D

Feb 26, 2025 9:40am

Judo throws down $100M to knock out kidney disease

Oct 7, 2024 10:42am

A sheet of paper reading venture capital

Amgen-partnered Plexium snags $102M for protein degraders

Feb 23, 2022 8:00am

Appia Bio aims for new off-the-shelf CAR-T with $52M raise

May 11, 2021 5:15am